
Opinion|Videos|May 21, 2024
Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events
A medical expert compares CDK4/6 inhibitors and discusses the importance of monitoring specific parameters, such as ECGs and laboratory tests, to minimize adverse events associated with each drug.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Pharmacists Can Close the Opioid Addiction Care Gap
2
FDA Approval Signals Broader Recognition of Sexual Health in Aging Women
3
Once-Weekly Retatrutide Reduces Weight and Knee Pain in Patients With Obesity and Osteoarthritis
4
US Measles Cases Climb, Raising Questions About Preparedness and Prevention
5


















































































































































































































